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Background: Several studies have found that Mexican Americans are less likely than Non-
Hispanic White Americans to use prescription drugs; however, the factors underlying this 
association remain unclear. We sought to evaluate the factors mediating the association between 
race/ethnicity and prescription drug use. We also investigated this association among persons 
with various health conditions to better understand differences in potential for unmet need. 
Methods: The exposure of interest was race/ethnicity, comparing Mexican Americans to Non-
Hispanic White Americans. The outcome was prescription drug usage within the past 30 days 
(yes vs no). Several variables were assessed as potential mediators. The percentage mediated and 
its respective 95% CI was calculated using bootstrapping with 1000 repetitions. Significant 
mediators were included in a joint difference mediation model that was analyzed using 
multinomial logistic regression. We also looked at those with diabetes, hypertension, 
hyperlipidemia, or depression. Logistic regression models were used to calculate odds ratios 
(unadjusted and fully adjusted) and their 95% CIs for the association between race/ethnicity and 
use of a prescription drug class corresponding to the condition. 
Results: Non-Hispanic whites were more likely to have taken prescription drugs in the past 30 
days than Mexican Americans (67.2% vs 37.5%). The joint mediation model mediated 44.3% of 
the relationship between race/ethnicity and prescription drug use. Among those with diabetes, 
Mexican Americans were more likely to be treated with an antidiabetic. Among those with 
hypertension, hyperlipidemia, or depression, Mexican Americans were less likely to be treated 
than Non-Hispanic whites, with hypertension and depression having statistically significant 
unadjusted and fully adjusted models. 
Conclusions: The association between race/ethnicity and prescription drug use is partially 
mediated by age, poverty income ratio, and variables reflecting health access. Disparities in 
prescription drug use persist among those with hypertension and depression. Further 
investigations should be done to better understand this disparity and the underlying factors 









Prescription drug use has been increasing in the United States over the last two decades, with 
nearly one in two Americans reporting using at least one prescription drug in the past 30 days 
between 2013-20161,2. This likely reflects several national health trends including an aging 
population, an increasing prevalence of obesity-related chronic illnesses, and physician over-
prescription3,4,5. However, in 2011-2012, Mexican Americans were half as likely (33%) to report 
taking any prescription drugs in the past 30 days compared to Non-Hispanic white Americans 
(66%)1.  
There are several hypotheses as to why we observe a lower prevalence of prescription drug use 
in Mexican Americans. The first is that, overall, Mexican Americans have a younger age 
distribution compared to Non-Hispanic white Americans6. A younger age distribution would be 
expected to lead to lower prevalence of prescription drug use since prescription drug use 
increases with age; for example, in 2015-2016, 18% of children under 12 reported use of 
prescription drugs, as compared to 85% of adults ages 60 and older7. Another possibility is the 
“Hispanic Paradox,” which describes the epidemiological phenomenon that, despite lower 
socioeconomic status (SES) and health-care access compared to their white counterparts, 
Mexican Americans tend to have better than expected health status8. This better health status 
would account for decreased need for prescription drugs. As mentioned above, Mexican 
Americans also have, on average, a lower socioeconomic status than Non-Hispanic white 
Americans8, which has generally been shown to be associated with worse access to healthcare 
and subsequent health outcomes9. We would expect lesser access to health care, especially those 
resulting from financial and language barriers, to contribute to lower physician diagnoses and 
prescriptions and, consequently, less use of drugs that require a prescription. However, it is 
currently uncertain which specific health determinants contribute to racial/ethnic differences in 
prescription drug use.  
In this project, we aimed to investigate the underlying mediators of the difference in prescription 
drug use between Mexican Americans and Non-Hispanic white Americans using nationally 
representative data from the National Health and Nutrition Examination Survey (NHANES). In 
secondary analyses, we further investigated the association between race/ethnicity (Mexican 
Americans vs. Non-Hispanic whites) and prescription drug use among persons with various 
health conditions to better understand differences in potential for unmet need.   
 
METHODS 
Study Population  
The National Health and Nutrition and Examination Survey (NHANES) is a nationally 
representative cross-sectional survey that is conducted every two years10. It consists of 
demographic, socioeconomic, dietary, and health-related questionnaires as well as a physical 
examination and laboratory testing10. In order to represent the total U.S. population, NHANES 
oversamples traditionally underrepresented populations including persons aged 60 and older, 
African Americans, and Hispanics. Thus, participants were assigned weights to account for 
unequal probabilities of selection and non-response1. For this study, the six cycles collected 
between 2005-2016 were chosen based on the availability of variables related to our exposure 
and outcome of interest.   
The sample size before and after our exclusion criteria were applied can be found in Figure 1. 
Our population of interest included Mexican American and Non-Hispanic white adults aged 25 
and older who participated in NHANES between 2005-2016. Those who self-identified as 
pregnant were excluded since prescription drug use changes for many people during pregnancy 
due to the potential harmful neonatal side effects. In order to conduct a complete case analysis 
without missing values for any of our variables, observations missing the exposure, outcome, or 
any covariates were excluded from the primary analysis - leaving us with a sample size of 16,537 
individuals. Of these individuals, 12,261 were Non-Hispanic white and 4,276 were Mexican 
American.  
Our secondary analysis was limited to those with one of four chronic conditions - diabetes, 
hypertension, hyperlipidemia, or depression. Thus, we created indicator variables to identify 
individuals who self-reported the aforementioned chronic conditions and excluded those who did 
not have any of these chronic conditions. This left us with a secondary analysis sample size of 
10,356 individuals out of the 16,537 from the primary analysis. This analysis included 8,488 
Non-Hispanic Whites and 1,868 Mexican Americans. This sample of 10,356 individuals 
included 2,169 with diabetes, 5,989 with hypertension, 3,748 with hyperlipidemia, and 1,037 
with depression. 
All analyses were weighted using dietary weights from NHANES due to our inclusion of five 
dietary measures: calories, sodium, fiber, saturated fat, and total fat. These weights, referred to as 
mobile examination centers (MEC) weights, were used to account for the inclusion of variables 





Our primary analysis sought to identify potential mediators of the difference in prescription drug 
use between Mexican Americans and Non-Hispanic white Americans. Race/ethnicity was the 
primary exposure and was limited to two groups - Mexican Americans and Non-Hispanic whites, 
with Non-Hispanic whites as the reference. Race/ethnicity was defined in NHANES by self-
reported questionnaire data in which participants were asked their race and ethnicity.  
The outcome of interest was prescription drug use. This behavior is captured in NHANES using 
self-reported questionnaire data in which participants were asked whether or not they had used or 
taken medication for which a prescription is needed in the past 30 days.   
  
Mediators 
Questionnaire data from NHANES was used to define the following mediators of interest: age, 
marital status, poverty income ratio (PIR), education level, general health condition, number of 
health visits per year, insurance/prescription drug coverage, quality of diet (good, very good, or 
excellent vs. fair or poor), physical activity level, smoking status, alcohol consumption, hours of 
sleep, and dietary factors (calories, sodium, fiber, saturated fat, and total fat). Due to prescription 
coverage by insurance plans being dependent on having insurance, insurance covering 
prescriptions was collapsed into one variable that encompassed both one’s type of insurance (if 
any) and whether or not an individual’s insurance covers prescription medications. Physical 
examination data were used to determine body mass index (BMI). Lastly, we utilized five dietary 
variables - calories, sodium, fiber, saturated fat, and total fat -from a two-day dietary recall. 
Detailed information on mediators is provided in Table 1. These variables were selected because 




As noted above, a priori, we selected the following mediators of interest: age, marital status, 
poverty income ratio (PIR), education level, general health condition, number of health visits per 
year, type of insurance, prescription coverage by insurance plan, quality of diet, physical activity 
level, smoking status, alcohol consumption, hours of sleep, and dietary factors (calories, sodium, 
fiber, saturated fat, and total fat). Chi-square tests were combined to determine which mediators 
were statistically significant in their association with both the exposure (race/ethnicity) and 
outcome (prescription drug use), since a variable can only mediate a given association 
if associated with exposure and outcome (Figure 2). We first evaluated the overall association 
between race/ethnicity and prescription drug use using logistic regression to calculate an 
unadjusted odds ratio (OR) and 95% confidence interval (95% CI). We then added each 
mediator, individually, to the model to evaluate the percentage of the association between 
race/ethnicity and prescription drug use that was mediated by that factor using a change in beta 
difference method using bootstrapping with 1000 repetitions to estimate 95% CIs11. Statistically 
significant mediators at the 𝛼=0.01 level were then used to construct a joint mediation model that 
was analyzed using logistic regression to evaluate their joint mediation of the association 
between race/ethnicity and prescription drug use.            
In order to address potential heterogeneity by subgroups in our study population, we conducted 
three sensitivity analyses. First, we conducted models with exposure alternatively separating 
(Mexican Americans born in U.S. and Mexican Americans moved to the U.S.). We also 
examined whether results varied by age (25-65y vs. ≥65y), and self-reported health status 
(poor/fair vs. good/very good/excellent).   
Secondary Analysis 
Chronic Condition Indicators 
In secondary analyses, we conducted four separate analyses, to examine the relationship between 
race/ethnicity and prescription drug usage exclusively among participants with one of four 
common chronic conditions - diabetes, hypertension, hyperlipidemia, and depression. Indicators 
for the four chronic conditions of interest in our secondary analysis were defined using a 
combination of self-reported and laboratory data. Specifically, an individual was defined as 
diabetic if they had been told they had diabetes by a doctor or their glycohemoglobin % was 
greater than or equal to 6.5%. We did not distinguish between Type 1 and Type 2 diabetes. 
Hypertension was defined as having been told an individual had high blood pressure by a doctor 
or having an average blood pressure reading (up to three total readings) above 140 systolic or 90 
diastolic12. Hyperlipidemia was only assessed for the cycles between 2005 and 2012 because the 
guidelines for prescribing statins changed in 2013. Using pre-2013 guidelines, hyperlipidemia 
was defined as an individual having been told by a doctor that they had high cholesterol or 
having total cholesterol at or above 240 mg/dL. Typically, dyslipidemia is diagnosed using 
lipoprotein cholesterol (LDL), but this measurement was only taken in a subset of NHANES 
participants13. Thus, to maximize the sample size, total cholesterol was the lab measure used to 
determine hyperlipidemia.  In order to assess depression, the responses from the nine-item 
Patient Health Questionnaire-9 (PHQ-9) depression screener were summed with responses “not 
at all,” “several days,” “more than half the days,” “nearly every day” corresponding to 0, 1, 2, 
and 3, respectively14. Individuals with a depression score of 10 or greater were defined as 
moderately to severely depressed. Those with a depression score of 5 or greater were defined as 
mildly to severely depressed and were not included in our initial secondary analysis.  
Exposure 
In these analyses, race/ethnicity was the exposure and was limited to two groups - Mexican 
Americans and Non-Hispanic whites. Race/ethnicity was defined in NHANES by self-reported 
questionnaire data in which participants were asked their race and Hispanic origin.  
 
Outcome 
The outcome for this analysis was taking a prescription drug for one of the four aforementioned 
chronic conditions. Indicators for the four prescription drug classes of interest in our secondary 
analysis were defined using the drug database in NHANES. Prescription medication information 
is collected from NHANES participants during the household interview1. Those who report 
taking a prescription medication in the past 30 days show the interviewer their prescription drug 
container, and the interviewer enters the drug information into the NHANES drug database. This 
information was used to create the definitions for our four drug classes: antidiabetics, 
antihypertensives, antihyperlipidemics, and antidepressants.   
Antidiabetic medications were defined as prescription drugs whose secondary level was 
classified under “Antidiabetic Agents.” Antihyperlipidemic medications were defined as 
prescription drugs whose secondary level was classified under “Antihyperlipidemic Agents.” 
Antidepressants were defined as prescription drugs whose secondary level was classified under 
“Antidepressants.” Lastly, antihypertensives were more precisely defined. Antihypertensives 
were any drug whose secondary categorical level was antihypertensive combinations, 




Within each given condition (e.g., individuals with diabetes), a logistic regression model was 
used to calculate odds ratios (unadjusted and fully adjusted) and their 95% CIs for the 
association between race/ethnicity and use of a given prescription drug class (e.g., in this case, 
anti-diabetics). Fully adjusted models included the four statistically significant mediators from 
the primary analysis - age, poverty income ratio, number of times healthcare was received in the 
past year, and health insurance prescription coverage - in order to evaluate associations over and 
above the factors mediating the relationship between race/ethnicity and prescription drug usage.  
All analyses were conducted using StataSE 16. Statistical significance was considered at the two-





The description of the population of interest and all potential mediators associated with the 
relationship between race/ethnicity and prescription drug usage can be seen in Table 1. Overall, 
the study population is 51.7% women and 48.3% men, where both percentages are weighted. Our 
analysis used data on 16,537 adults aged 25 and older. Our initial analysis confirmed that Non-
Hispanic whites report taking prescription drugs at a higher prevalence than Mexican Americans 
with 37.5% of Mexican Americans reporting use of a prescription drug in the past 30 days 
compared to 67.2% of Non-Hispanic whites.  
  
Table 2 displays the percentage of the relationship between race/ethnicity and prescription drug 
use mediated by each variable. Significant mediators were those that had negative values with 
95% CIs that did not include zero. This was the result of significant mediators being positively 
associated with either the exposure or outcome and negatively associated with the other. For 
example, we expected age to be negatively associated with race/ethnicity due to Mexican 
Americans having a younger age distribution than Non-Hispanic whites and positively associated 
with prescription drug use as prescription drug use tends to increase with age. Thus, age had a 
negative value for the percentage it mediated. 
  
A joint mediation model was then constructed including the four significant mediators (Table 3). 
These mediators were age, poverty income ratio, number of health visits in a year, and health 
insurance prescription coverage. This joint model mediated 44.3% [95% CI: 37.4%-51.4%] of 
the relationship between race/ethnicity and prescription drug use. Potential heterogeneity due to 
country of origin (for Mexican Americans), age, and health status led to rerunning our analyses 
using a redefined exposure for country of origin and stratification on age and health status (Table 
4). Mexican Americans were divided by whether they were born in the U.S. or moved to the 
U.S., and both groups were separately compared to and found to take prescription drugs at a 
lower prevalence than Non-Hispanic whites. However, Mexican Americans born in the U.S. had 
a much higher prevalence of prescription drug use (49.3%) compared to Mexican Americans that 
moved to the U.S. (29.0%). However, across both models, between 40-50% of the relationship 
between race/ethnicity and prescription drug use was mediated with 48.2% [95% CI: 34.2%-
66.0%] for Mexican Americans born in the U.S. and 41.1% [95% CI: 35.2%-48.6%] for Mexican 
Americans that moved to the U.S.  
We then ran additional sensitivity analyses to examine whether the results varied by age (<65 vs 
65+) and health status (good/very good/excellent vs poor/fair) (Table 4). We found that 
prescription drug usage was more disparate between our racial/ethnic groups in the younger age 
group (OR=0.45 [0.39, 0.51] vs. OR=0.61 [0.44, 0.83]), with both joint models mediating low 
but statistically significant percentages (28.4% and 31.0%) of the relationship between 




The prevalence of each of the four chronic conditions in our study population - both overall and 
broken down by race/ethnicity - can be seen in Table 5. The overall population had prevalences 
of 15.8%, 52.7%, 51.3%, and 8.9% for diabetes, hypertension, hyperlipidemia, and depression, 
respectively. Mexican Americans saw higher prevalences of diabetes, hypertension, and 
depression compared to Non-Hispanic whites. All conditions had less than 5% missingness.  
 
Table 6 contains the unadjusted and fully adjusted logistic regression models for the use of 
prescription medications to treat chronic conditions among those with the corresponding chronic 
conditions by race/ethnicity. Among those with diabetes, we saw that Mexican Americans 
(80.8%) were more likely than Non-Hispanic whites (77.0%) to have taken a prescription 
antidiabetic in the past 30 days (OR=1.25, 95% CI: [0.93, 1.69]). The odds ratio was relatively 
unaffected (OR=1.28, 95% CI: [0.95, 1.72]) by adjusting for age, poverty income ratio, number 
of times health care was received in the past year, and health insurance prescription coverage. 
For the other three chronic conditions (hypertension, hyperlipidemia, and depression), Mexican 
Americans were less likely to be treated than Non-Hispanic whites. The greatest disparity was 
seen among those with depression, where Mexican Americans had a much lower prevalence 
(33.5% treated) and half the odds of their depression being treated with an antidepressant 
compared to Non-Hispanic whites (50.0% treated). The depression analysis was also conducted 
to include those with mild depression (depression questionnaire scores >= 5) in order to compare 
the racial/ethnic disparity in antidepressant use when depression is defined less conservatively. 
The models yielded nearly identical odds ratios (OR=0.53 unadjusted, 95% CI: [0.39, 0.74] vs. 
OR=0.56 fully adjusted, 95% CI: [0.40, 0.79]) as those that excluded people with mild 
depression (OR=0.50 unadjusted, OR=0.55 fully adjusted). 
Among those with hypertension, Mexican Americans had a lower prevalence (54.1%) and 0.66 
the odds of their hypertension being treated with an antihypertensive compared to Non-Hispanic 
whites (64.2%). Lastly, Mexican Americans and Non-Hispanic whites with hyperlipidemia had 
comparable prevalences (50.1% vs. 51.0%, respectively) of treatment with an antihyperlipidemic 
which led to an unadjusted odds ratio of 0.97 with an insignificant 95% confidence interval of 





Through these analyses, we found evidence of a disparity in prescription drug usage between 
Mexican Americans and Non-Hispanic white Americans as well as several factors that mediate 
this relationship. Specific variables that affected the relationship include age, poverty income 
ratio, number of health care visits, as well as health insurance and prescription coverage.  
  
Initial analyses confirmed the disparity in prescription drug use with 37.5% of Mexican 
Americans in our study taking a prescription drug in the past 30 days compared to 67.2% of 
Non-Hispanic whites. Our primary analysis then showed that, even with significant mediators 
included in the joint model, the odds of Mexican Americans taking prescription drugs were one-
half times those of Non-Hispanic whites. Moreover, only less than half of the relationship 
between race/ethnicity and prescription drug use was mediated by age, poverty income ratio, 
health care access, as well as health insurance and prescription coverage. Overall, much of the 
disparity in prescription drug use between Mexican Americans and Non-Hispanic white 
Americans was unexplained by our joint model. It is also worth noting that prescription drug use 
alone may not be entirely predictive of health outcomes, with one study showing that 
prescription drug coverage had little effect on health or hospitalization among elderly people15.  
  
Another factor we wanted to consider was immigration/nativity status as this has been shown to 
affect self-perceived quality of care among Latino Americans16. In the sensitivity analysis 
separating Mexican Americans by country of origin, we found that Mexican Americans born in 
the U.S. were more similar to Non-Hispanic whites than those who moved to the U.S. in terms of 
prescription drug use, though the joint models for both mediated 40%-50% of the relationship 
between race/ethnicity and prescription drug use. A potential contributing factor that was not 
considered in this study was citizenship status. One study has shown that undocumented Latinos 
in particular were less likely to report having received excellent/good quality of care and more 
likely to receive no health/health-care information from doctors16. Stratifying by health status 
demonstrated that the racial/ethnic disparity in prescription drug use does not largely vary by 
health status. When we stratified by age, we did see that the racial/ethnic disparity in prescription 
drug use was smaller in people 65 and older. It is possible that this smaller disparity could be 
attributable to Medicare, with prior research indicating that the introduction of Medicare Part D 
led to reductions in out-of-pocket costs for prescription drugs17. Ultimately, none of our 
mediation models came particularly close to fully accounting for the relationship between 
race/ethnicity and prescription drug use.  
Our secondary analysis showed that, among those with hypertension and depression, Mexican 
Americans were less likely to be treated with an appropriate prescription medication than Non-
Hispanic whites. Prior to this study, we knew that there was evidence that Mexican Americans 
were less likely to report taking a prescription drug in the past 30 days compared to Non-
Hispanic whites; however, this analysis showed that this disparity persists even among those 
with hypertension and depression, reflecting unmet need in those that need the appropriate 
medications most.   
Among those with diabetes, we saw that Mexican Americans were slightly more likely to be 
treated for diabetes with an antidiabetic than Non-Hispanic whites, though this result was not 
statistically significant. The odds ratios reflecting this were relatively unaffected by adjusting for 
age, poverty income ratio, number of health care visits, and health insurance and prescription 
coverage. It is possible that our capture of diabetes was reflected by only using one lab value. 
We were unable to use fasting glucose lab values due to weighting variables that would have 
reduced our sample size. This could have introduced selection bias if our capture of diabetes 
would have differed between racial/ethnic groups had we used more lab values, particularly if 
those not captured by the glycohemoglobin measure varied from those who were. If this were the 
case, we may have seen a higher prevalence of diabetes among Mexican Americans or that they 
were less likely to be treated with an antidiabetic than Non-Hispanic whites. It is also possible 
that the glycohemoglobin levels we did use were, on average, higher for Mexican Americans.  In 
an analysis of predictors of glycohemoglobin in nondiabetic children 4 to 17 years of age, 
researchers found that Mexican Americans had higher mean HbA1c levels than Non-Hispanic 
whites after controlling for age, sex, BMI, maternal BMI, and poverty-income ratio18. We would 
expect that higher average glycohemoglobin levels for Mexican Americans with diabetic A1c 
levels may lead to a greater likelihood of treatment. 
Among those with hypertension, Mexican Americans were less likely to be treated for 
hypertension than Non-Hispanic whites, although this association attenuated and was only 
statistically significant in the unadjusted model. This could tell us that the difference in 
hypertension treatment is affected by any of the factors included in our fully adjusted models. 
For example, health insurance may have played a large role as one study has shown that 
uninsured Mexican Americans had significantly lower rates of hypertension awareness, 
treatment, and control than Mexican Americans on Medicaid19. Though neither model was 
statistically significant, we also saw a noticeable difference between the unadjusted and adjusted 
models for hyperlipidemia, though Mexican Americans and Non-Hispanic whites had very 
similar prevalences of treatment with an antihyperlipidemic. The difference between the 
unadjusted and adjusted models could be a reflection of the impacts of the health visits and 
health insurance and prescription coverage mediators rather than poverty income ratio as one 
study reported that differences in lipid levels in Hispanic subgroups could not be explained by 
financial strain20.  
We saw the largest treatment disparity among those with depression. In both our unadjusted 
model and after adjusting for the significant mediators from the primary analysis, Mexican 
Americans had approximately half the odds of taking an antidepressant compared with Non-
Hispanic whites. Here, it is important to note that our only metric for depression in this analysis 
was the PHQ-9, which has several complications. First, those who are already being treated for 
depression may be less likely to score a 10 or higher on the PHQ-9, which would drive down the 
prevalence of depression in our sample. Since Non-Hispanic whites are more likely to be treated 
than Mexican Americans, this could have led to selection bias. Moreover, mental health is 
perceived and stigmatized differently in different racial and ethnic groups21. Thus, it is possible 
that Mexican American NHANES participants may respond to the PHQ-9 differently on average 
than Non-Hispanic whites.  Research has shown that Hispanic Americans are less likely to 
perceive themselves as having mental illness or requiring mental health treatment, which could 
make them less likely to recognize that they are depressed and seek out treatment for their 
depression21.  It is also worth noting that only 8.9% of the 10,356 participants in our secondary 
analysis were found to have depression. This percentage is in line with the national prevalence of 
depression, with 8.1% of adults 20 and over reporting experiences of depression over a two-week 
period between 2013-201622. Unlike the other chronic conditions examined in this study, 
depression is entirely based on self-reported data (i.e., the PHQ-9 questionnaire) and lacks a 
question as to whether or not a respondent has been told by a doctor that they have depression. 
Thus, it is possible that depression was not fully captured in our study population as people with 
depression who are taking antidepressants may not have scored a 10 or above on the depression 
screener. The inability to include those taking antidepressants, as this was an outcome for this 
analysis, could have also contributed to the low prevalence of depression in our study. When we 
ran a sensitivity analysis to include those with mild forms of depression, we found that, although 
we captured twice as many people with depression, the ORs in our unadjusted and fully adjusted 
logistic regression models were very similar to those that only included those with moderate to 
severe forms of depression. This indicates that the observed racial/ethnic disparity in 
antidepressant treatment among those with depression persists among those with mild to severe 
forms of depression as well as moderate to severe forms of depression.     
The methods and dataset used for this study came with different strengths and limitations. 
NHANES is a large, nationally representative dataset that contains a comprehensive inventory of 
all prescription drugs taken by survey respondents. Additionally, we had a well-powered analysis 
conducted in a large, nationally representative study. Our mediation analysis was built on 
mediation methods relationships between race/ethnicity and prescription drug use. However, 
there are several limitations to consider. Our outcome variable of prescription drug use is limited 
to the past 30 days of when a respondent was interviewed. This led to the exclusion of chronic 
conditions in our secondary analysis for which we know a large disparity in prescription drug use 
exists. For example, we know that use of bronchodilators is less prevalent among Mexican 
Americans than Non-Hispanic whites1; however, we did not examine this drug class. We know 
that an asthmatic person may require a prescription inhaler but not use it on a monthly basis. 
Additionally, our study was not geographically representative for any particular region in the 
U.S. and is only generalizable to the entire country. Moreover, there was some missingness of 
covariate data; however, it was not extensive. Despite these limitations, these findings are a 
valuable contribution to the existing literature, highlighting where racial disparities in medication 
access and use exist. 
In summary, in this study, we observed a racial/ethnic disparity in the prevalence of prescription 
drug use between Mexican Americans and Non-Hispanic whites. This disparity was less 
apparent in those over 65 and Mexican Americans who moved to the U.S., but it persisted among 
those with better and worse health status. This disparity was also less notable among those with 
diabetes and those with hyperlipidemia; the association held for those with hypertension and 
those with depression. More work is needed to better understand this disparity and the 




















































































Table 1. Population Characteristics by Race/Ethnicity 
 Total  
Sample 
N=16,537 




N (Weighted %) 
Mexican American 
N=4,276 
N (Weighted %) 
Sociodemographics    
Age (years)    
     25-39 4540 (28.1) 3103 (26.0) 1437 (45.9) 
     40-49 2987 (20.1) 2095 (19.7) 892 (24.0) 
     50-64 4224 (29.9) 2994 (30.9) 1230 (20.8) 
     65-79 3288 (16.5) 2661 (17.5) 627 (8.0) 
     80+ 1498 (5.4) 1408 (5.9) 90 (1.3) 
Marital Status    
     Never Married, Divorced/  
        Separated, or Widowed                                  
5479 (30.9) 4230 (31.2) 1249 (28.0) 
     Married/Living with           
        Partner 
11,058 (69.1) 8031 (68.8) 3027 (72.0) 
Socioeconomic Status    
Poverty Income Ratio 
(PIR) 
   
     <1 (Lower Income) 2831 (10.1) 1637 (8.2) 1194 (26.4) 
     1-1.99 4164 (17.7) 2895 (16.3) 1269 (29.9) 
     2-3.99 4042 (27.5) 3152 (28.1) 890 (21.5) 
     ≥4 (Higher Income) 4396 (39.4) 3935 (42.5) 461 (11.9) 
     Refused/Don’t Know/  
        Missing 
1104 (5.3) 642 (4.8) 462 (10.2) 
Education    
     Less Than 9th Grade, 9-       
        11th Grade, High 
8155 (37.9) 4997 (34.2) 3158 (69.9) 
        School Grad/GED  
     Some College or AA    
        Degree, College Grad, 
8382 (62.1) 7264 (65.8) 1118 (30.1) 
        Graduate School 
Health Status1    
General Health Condition    
     Good, Very Good,    
        Excellent 
12,477 (83.1) 9922 (85.3) 2555 (63.9) 
     Fair or Poor 4060 (16.9) 2339 (14.7) 1721 (36.1) 
Health Access    
Number of times health 
care was received in the 
past year 
   
     0 2561 (14.1) 1435 (12.2) 1126 (30.1) 
     1-2 7099 (46.0) 5217 (46.2) 1882 (44.4) 
     3-4 4994 (28.7) 4047 (29.8) 947 (18.8) 
     5+ 1883 (11.2) 1562 (11.7) 321 (6.7) 
Health Insurance Covers 
Prescriptions 
   
     No Insurance 3462 (15.2) 1649 (11.6) 1813 (46.6) 
     Public Insurance, No Rx   
        Coverage        
430 (1.9) 326 (1.8) 104 (2.5) 
     Public Insurance, Rx  
        Coverage 
3374 (15.9) 2512 (15.9) 862 (16.0) 
     Private Insurance, No Rx  
        Coverage 
583 (3.4) 474 (3.6) 109 (2.4) 
     Private Insurance, Rx  
        Coverage 
8688 (63.6) 7300 (67.1) 1388 (32.6) 
Lifestyle Factors    
Quality of Diet    
     Good, Very Good,  
        Excellent 
11,918 (76.1) 9489 (78.4) 2429 (56.3) 
     Fair or Poor 4619 (23.9) 2772 (21.6) 1847 (43.7) 
BMI     
     Underweight or Normal 4301 (28.0) 3567 (29.1) 734 (18.3) 
     Overweight 5996 (35.8) 4326 (35.5) 1670 (38.0) 
     Obese 6240 (36.2) 4368 (35.4) 1872 (43.7) 
Physical Activity    
     Vigorous  5409 (38.0) 4103 (38.2) 1306 (36.0) 
     Moderate 5396 (34.0) 4273 (34.9) 1123 (25.8) 
     None 5732 (28.1) 3885 (26.9) 1847 (38.2) 
Smoking    
     Never 8335 (51.3) 5692 (50.0) 2643 (63.5) 
     Former 4820 (28.6) 3848 (29.5) 972 (20.2) 
     Current  3382 (20.1) 2721 (20.5) 661 (16.3) 
Alcohol Consumption 
(Frequency of 
consumption in past 12 
months) 
   
					<1 / month 7315 (37.7) 5205 (37.0) 2110 (44.0) 
     ≥1 / month – 4 / week 4482 (30.2) 3389 (30.4) 1093 (28.6) 
     ≥4 / week – <2 / day 2964 (21.2) 2390 (22.0) 574 (14.8) 
     ≥2 / day 896 (6.2) 694 (6.3) 202 (5.1) 
     Refused/Don’t  
        Know/Missing 
880 (4.6) 583 (4.3) 297 (7.5) 
Hours of Sleep (2005-2014)    
     ≤ 6 4900 (33.5) 3621 (33.2) 1279 (35.7) 
     7 4083 (30.9) 3150 (31.3) 933 (27.4) 
     8-9 4790 (33.4) 3588 (33.3) 1202 (34.3) 
     10+ 397 (2.2) 316 (2.2) 81 (2.6) 
Dietary Factors2    
Calories    
     Q1 3095 (16.3) 2177 (16.1) 918 (18.2) 
     Q2 4068 (24.5) 3107 (24.9) 961 (21.2) 
     Q3 4595 (28.8) 3444 (28.9) 1151 (28.1) 
     Q4 4779 (30.4) 3533 (30.2) 1246 (32.6) 
Sodium    
     Q1 4139 (21.5) 2852 (21.0) 1287 (25.9) 
     Q2 4131 (25.0) 3118 (25.2) 1013 (23.1) 
     Q3 4136 (26.2) 3165 (26.5) 971 (23.8) 
     Q4 4131 (27.3) 3126 (27.3) 1005 (27.2) 
Fiber    
     Q1 4146 (24.0) 3366 (24.7) 780 (17.5) 
     Q2 4130 (25.5) 3210 (25.9) 920 (21.8) 
     Q3 4138 (25.5) 3034 (25.5) 1104 (25.6) 
     Q4 4123 (25.0) 2651 (23.9) 1472 (35.1) 
Saturated Fat    
     Q1 4135 (22.2) 2805 (21.5) 1330 (27.8) 
     Q2 4134 (24.7) 3059 (24.7) 1075 (24.2) 
     Q3 4134 (25.8) 3159 (26.1) 975 (23.4) 
     Q4 4134 (27.3) 3238 (27.6) 896 (24.5) 
Total Fat    
     Q1 4135 (21.9) 2833 (21.4) 1302 (26.6) 
     Q2 4137 (24.9) 3100 (25.0) 1037 (23.9) 
     Q3 4131 (25.8) 3151 (26.0) 980 (24.1) 
     Q4 4134 (27.4) 3177 (27.6) 957 (25.5) 
1 Self-reported 
2 Dietary variables have the following minimum cutoff points: calories (kcal) [Q2= 1485.5, Q3 
=1938, Q4=2487.5]; sodium (mg) [Q2=2336, Q3=3122, Q4=4113]; fiber (gm) [Q2=11.05, 
Q3=15.75, Q4=22], saturated fat (gm) [Q2=16.1895, Q3=23.339, Q4=32.733]; total fat (gm) 














Table 2. Unadjusted Logistic Regression Model for Mediators Predicting the Effect of 
Race/Ethnicity (Non-Hispanic White Americans vs. Mexican Americans) on Prescription Drug 
Use  
Mediator Odds Ratio  
(Race/Ethnicity & Prescription 
Drug Use) 
% mediated  
% (95% CI) 
Exposure (No Mediator) 
Race/Ethnicity (MA vs. NHW)1 0.29 N/A 
Sociodemographics 
Gender  0.29 0.5 (-0.6, 1.6) 
Age (years)  0.39 -22.6 (-26.2, -19.5) 
Poverty Income Ratio (PIR)  0.30 -2.6 (-4.8, -0.7) 
Health Status 
General Health Condition 0.21 25.5 (21.4, 30.1) 
Health Access 
Number of times health care 
was received in the past year  
0.36 -17.6 (-22.0, -13.2) 
Health Insurance Prescription 
Coverage 
0.36 -17.7 (-21.0, -14.5) 
Lifestyle Factors 
Quality of Diet  0.29 -0.4 (-2.1, 1.4) 
BMI in kg/m2  0.27 6.2 (4.6, 8.2) 
Physical Activity  0.27 7.7 (5.9, 10.1) 
Smoking  0.29 0.3 (-0.5, 1.4) 
Alcohol Consumption 
(Frequency of consumption in 
past 12 months)  
0.28 2.7 (1.6, 4.0) 
Hours of Sleep (2005-2014)  0.28 0.3 (0.1, 1.0) 
Dietary Factors   
Calories  0.29 1.8 (0.6, 3.1) 
Sodium  0.28 1.9 (0.6, 3.3) 
Fiber  0.28 2.8 (1.2, 4.6) 
Saturated Fat  0.29 1.2 (-0.2, 2.7) 
Total Fat  0.29 0.9 (-0.6, 2.4) 
1 Mexican American and Non-Hispanic white were abbreviated to MA and NHW, respectively. 
 
 
Table 3. Unadjusted Joint Logistic Regression Model1 for Mediators Predicting the Effect of 
Race/Ethnicity (Non-Hispanic White Americans vs. Mexican Americans) on Prescription Drug 
Use 
Odds Ratio (Race/Ethnicity & Rx Use) 
(95% CI) 
% jointly mediated  
% (95% CI) 
0.50 (0.44, 0.57) -44.25 (-51.41, -37.44) 
1The mediators included in the joint model were age, poverty income ratio, number of times 
health care was received in the past year, and health insurance prescription coverage. 
Table 4.  Joint Logistic Regression Models for Mediators Predicting the Effect of Race/Ethnicity 





















0.39 (0.33, 0.45) -41.1 (-48.6, -35.2) Age, Number of 












≥ 65 0.61 (0.44, 0.83) -31.0 (-58.9, -11.4) Number of Health 




< 65 0.45 (0.39, 0.51) -28.4 (-35.8, -21.6) PIR, Number of 








0.38 (0.28, 0.50) -42.6 (-52.7, -31.8) Age, PIR, Number 










0.44 (0.37, 0.52) -44.3 (-55.6, -39.4) Age, PIR, Number 










Table 5. Chronic Conditions by Race/Ethnicity 
 Total  
Sample 
N=10,356 




N (Weighted %) 
Mexican American 
N=1,868 
N (Weighted %) 
Diabetes    
     Yes 2169 (15.8) 1483 (14.8) 686 (31.6) 
     No 7952 (82.0) 6802 (82.9) 1150 (66.5) 
     Missing 235 (2.3) 203 (2.3) 32 (1.9) 
Hypertension    
     Yes 5989 (52.7) 4863 (52.6) 1126 (54.4) 
     No 4268 (46.5) 3543 (46.6) 725 (44.8) 
     Missing 99 (0.8) 82 (0.8) 17 (0.9) 
Hyperlipidemia (2005-
2012) 
   
     Yes 3748 (51.3) 3126 (51.5) 622 (47.7) 
     No 3171 (45.1) 2642 (44.9) 529 (47.8) 
     Missing 310 (3.7) 248 (3.6) 62 (4.5) 
Depression    
     Yes 1037 (8.9) 819 (8.6) 218 (12.4) 
     No 8794 (87.1) 7265 (87.4) 1529 (81.5) 




Table 6. Logistic regression model for the use of prescription medications to treat chronic 
conditions among those with the corresponding chronic conditions by race/ethnicity  
1The mediators included in the joint models were age, poverty income ratio, number of times 










OR (95% CI) 
Fully adjusted1 
OR (95% CI) 
Among those with diabetes 
   Non-Hispanic White 1131 (77.0) 352 (23.0) 1.00 (ref) 1.00 (ref) 
   Mexican American 568 (80.8) 118 (19.2) 1.25 (0.93, 1.69) 1.28 (0.95, 1.72) 
Among those with hypertension 
   Non-Hispanic White 3268 (64.2) 1595 (35.9) 1.00 (ref) 1.00 (ref) 
   Mexican American 665 (54.1) 461 (45.9) 0.66 (0.54, 0.81) 0.84 (0.68, 1.02) 
Among those with hyperlipidemia (2005-2012) 
   Non-Hispanic White 1709 (51.0) 1417 (49.0) 1.00 (ref) 1.00 (ref) 
   Mexican American 339 (50.1) 283 (49.9) 0.97 (0.75, 1.25) 1.35 (1.02, 1.79) 
Among those with depression 
   Non-Hispanic White 404 (50.0) 415 (50.0) 1.00 (ref) 1.00 (ref) 
   Mexican American 66 (33.5) 152 (66.5) 0.50 (0.34, 0.75) 0.55 (0.36, 0.83) 
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